Grifois, S.A. (GRFS)

Price$7.74

Value ScoreB

Growth ScoreC

Momentum ScoreF

Favorite Metrics

Price vs S&P 500 (26W)-24.46%

Price vs S&P 500 (4W)-3.06%

VGM Score40.29

Market Capitalization$6.75B

P/E Ratio (Annual)14.41x

Indicated Dividend Yield (Annual)0.00%

All Metrics

P/CF (Annual)5.53x

Book Value / Share (Quarterly)$9.35

P/TBV (Annual)2.58x

Indicated Dividend (Annual)$0.17

Revenue Growth (3Y)7.46%

Cash Flow / Share (Quarterly)$1.02

Payout Ratio (TTM)56.83%

Price vs S&P 500 (YTD)-23.38%

Gross Margin (TTM)37.43%

Net Profit Margin (TTM)5.58%

EPS (TTM)$0.78

10-Day Avg Trading Volume4.12M

EPS Excl Extra (TTM)$0.78

Revenue Growth (5Y)7.10%

EPS (Annual)$0.69

Dividend / Share (Annual)$0.22

ROI (Annual)2.70%

Gross Margin (Annual)38.00%

Net Profit Margin (5Y Avg)3.14%

Cash / Share (Quarterly)$1.30

P/E Basic Excl Extra (TTM)13.95x

Revenue Growth QoQ (YoY)-4.81%

EPS Growth (5Y)-8.12%

P/E Normalized (Annual)14.41x

ROA (Last FY)2.04%

Revenue Growth TTM (YoY)0.89%

EBITD / Share (TTM)$2.99

ROE (5Y Avg)3.64%

Operating Margin (TTM)16.47%

Cash Flow / Share (Annual)$1.07

P/B Ratio1.06x

P/B Ratio (Quarterly)1.02x

Net Income / Employee (Annual)$18,529

EV / Revenue (TTM)1.98x

Net Interest Coverage (TTM)2.22x

ROA (TTM)2.09%

EPS Growth QoQ (YoY)96.81%

EV / EBITDA (TTM)9.29x

EPS Incl Extra (Annual)$0.69

Current Ratio (Annual)2.51x

Quick Ratio (Quarterly)0.85x

3-Month Avg Trading Volume2.43M

52-Week Price Return-3.93%

EV / Free Cash Flow (Annual)23.65x

P/E Incl Extra (TTM)13.95x

Revenue / Employee (TTM)$343,188

Tangible BV / Share (Quarterly)$4.35

P/S Ratio (Annual)0.77x

Asset Turnover (Annual)0.38x

52-Week High$13.70

Operating Margin (5Y Avg)14.07%

EPS Excl Extra (Annual)$0.69

CapEx CAGR (5Y)7.44%

Tangible BV CAGR (5Y)-6.46%

26-Week Price Return-8.53%

Quick Ratio (Annual)0.88x

13-Week Price Return-15.33%

Total Debt / Equity (Annual)1.83x

Current Ratio (Quarterly)2.47x

Enterprise Value$17.20B

Revenue / Share Growth (5Y)7.25%

Asset Turnover (TTM)0.37x

Book Value / Share Growth (5Y)0.75%

Revenue / Employee (Annual)$347,150

Inventory Turnover (Annual)1.36x

Pretax Margin (Annual)8.17%

Cash / Share (Annual)$1.43

3-Month Return Std Dev34.56%

Gross Margin (5Y Avg)38.23%

Net Income / Employee (TTM)$19,111

EBITDA CAGR (5Y)4.77%

EBITDA Interim CAGR (5Y)7.68%

ROE (Last FY)7.63%

Net Interest Coverage (Annual)2.37x

EPS Basic Excl Extra (Annual)$0.69

P/FCF (TTM)9.72x

Receivables Turnover (TTM)7.45x

EV / Free Cash Flow (TTM)24.76x

Total Debt / Equity (Quarterly)1.77x

EPS Incl Extra (TTM)$0.78

Receivables Turnover (Annual)10.20x

ROI (TTM)2.85%

Dividend Growth Rate (5Y)2.54%

P/S Ratio (TTM)0.78x

Pretax Margin (5Y Avg)6.16%

Revenue / Share (Annual)$12.88

Tangible BV / Share (Annual)$4.35

Forward P/E9.79x

Price vs S&P 500 (52W)-32.14%

P/E Ratio (TTM)13.95x

EPS Growth TTM (YoY)135.98%

Year-to-Date Return-13.27%

5-Day Price Return-4.29%

EPS Normalized (Annual)$0.69

ROA (5Y Avg)1.00%

Net Profit Margin (Annual)5.34%

Month-to-Date Return3.57%

EBITD / Share (Annual)$2.42

EPS Growth (3Y)24.46%

Operating Margin (Annual)16.48%

LT Debt / Equity (Annual)1.55x

P/CF (TTM)5.67x

ROI (5Y Avg)1.31%

P/E Excl Extra (TTM)13.95x

LT Debt / Equity (Quarterly)1.66x

EPS Basic Excl Extra (TTM)$0.78

P/TBV (Quarterly)2.58x

Payout Ratio (Annual)31.84%

P/B Ratio (Annual)1.25x

Dividend / Share (TTM)$0.22

Inventory Turnover (TTM)1.33x

Pretax Margin (TTM)8.22%

Book Value / Share (Annual)$9.03

Price vs S&P 500 (13W)-25.07%

Net Margin Growth (5Y)-14.34%

Dividend Yield (TTM)2.21%

Beta0.67x

P/FCF (Annual)9.28x

Revenue / Share (TTM)$20.52

ROE (TTM)7.88%

52-Week Low$8.43

vGradeB

gGradeC

mGradeF

vgmGradeC

Show chart for

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

3.86

3.81

About

Grifols is a global specialty plasma therapeutics company that develops, manufactures, and distributes protein-based medicines for immunological deficiencies, hemophilia, and other chronic and life-threatening conditions. The company's portfolio serves both diagnostic and therapeutic applications across rare and inherited diseases with significant unmet medical needs. Grifols generates the majority of its revenue from the United States market.